Mesenchymal stromal cells impair the differentiation of CD14⁺⁺ CD16⁻ CD64⁺ classical monocytes into CD14⁺⁺ CD16⁺ CD64⁺⁺ activate monocytes

References

• Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6: 230–47.
   PubMed Web of Science ®Google Scholar
• Da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204–13.
   PubMed Web of Science ®Google Scholar
• Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 2006;20:161–71.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, . Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–36.
   PubMed Web of Science ®Google Scholar
• Schäfer R, Northoff H. Cardioprotection and cardiac regeneration by mesenchymal stem cells. Panminerva Med. 2008; 50:31–9.
   Google Scholar
• Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY, . A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28:1099–106.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, . Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–43.
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42–8.
   PubMed Web of Science ®Google Scholar
• Yang M, Wei X, Li J, Heine LA, Rosenwasser R, Iacovitti L. Changes in host blood factors and brain glia accompanying the functional recovery after systemic administration of bone marrow stem cells in ischemic stroke rats. Cell Transplant. 2010;19:1073–84.
   PubMed Web of Science ®Google Scholar
• Zhao MZ, Nonoguchi N, Ikeda N, Watanable T, Furutama D, Miyazawa D, . Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab. 2006;26:1176–88.
   PubMed Web of Science ®Google Scholar
• Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, . Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol. 2000;18:307–16.
   PubMed Web of Science ®Google Scholar
• Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, . Cotransplantation of ex-vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007;110:2764–7.
   PubMed Web of Science ®Google Scholar
• Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trial. Bone Marrow Transplant. 2009;43:447–54.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, . Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lance. 2004;363:1439–41.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ge W, Li C, You S, Liao L, Han Q, . Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004;13:263–71.
   PubMed Web of Science ®Google Scholar
• Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, . Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105:2214–9.
   PubMed Web of Science ®Google Scholar
• Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, . Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005; 105:4120–6.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34 + -derived and monocyte-derived dendritic cells. J Immunol. 2006;177:2080–7.
   PubMed Web of Science ®Google Scholar
• Jung YJ, Ju SY, Yoo ES, Cho SJ, Cho KA, Woo SY, . MSC-DC interaction: MSC inhibit maturation and migration of BM-derived DC. Cytotherapy. 2007;9:451–8.
   PubMed Web of Science ®Google Scholar
• Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, . Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007;25:2025–32.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007;83:71–6.
   PubMed Web of Science ®Google Scholar
• English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett. 2008:115:50–8.
   PubMed Web of Science ®Google Scholar
• Li YP, Paczesny S, Lauret E, Poirault S, Bordigoni P, Mekhloufi F, . Human mesenchymal stem cells license adult CD34+ hemohemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol. 2008;180:1598–608.
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 2009; 113:6576–83.
   PubMed Web of Science ®Google Scholar
• Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, . Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15:42–9.
   PubMed Web of Science ®Google Scholar
• Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. 2009;37:1445–53.
   PubMed Web of Science ®Google Scholar
• Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, Nepomnaschy I, . Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS ONE. 2010;5:1–13.
   Google Scholar
• Groh ME, Maitra B, Szekely E, Koç ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol. 2005;33:928–34.
   PubMed Web of Science ®Google Scholar
• Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–64.
   PubMed Web of Science ®Google Scholar
• Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol. 2001;69:11–20.
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock, HW. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today. 1996;17:424–8.
   PubMedGoogle Scholar
• Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669–92.
   PubMed Web of Science ®Google Scholar
• Skrzeczynska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M, Pryjma J. Peripheral blood CD14hi CD16+ monocytes are main producers of IL-10. Scand J Immunol. 2007;67:152–9.
   Google Scholar
• Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81:584–92.
   PubMed Web of Science ®Google Scholar
• Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiol. 2006;211:609–18.
   PubMed Web of Science ®Google Scholar
• Yrlid U, Jenkins CD, MacPherson GG. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J Immunol. 2006;176:4155–62.
   Google Scholar
• Ancuta P, Liu K-Y, Misra V, Wacleche VS, Gosselin A, Zhou X, . Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16− monocyte subsets. BMC Genomics. 2009;10:1–19.
   PubMedGoogle Scholar
• S nchez-Torres C, Garc a-Romo GS, Cornejo-Cort s MA, Rivas-Carvalho A, S nchez-Schmitz G. CD16+ and CD16− human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol. 2001;13:1571–81.
   Google Scholar
• Jakubzick C, Tacke F, Ginhoux F, Wagners AJ, van Rooijen N, Mack M, . Blood monocyte subsets differentially give rise to CD103+ and CD103− pulmonary dendritic cell populations. J Immunol. 2008;180:3019–27.
   PubMed Web of Science ®Google Scholar
• Randolph GJ, Sanchez-Schmitz G, Liebman RM, Schäkel K. The CD16+ (FcγRIII+) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med. 2002;196:517–27.
   PubMedGoogle Scholar
• Grage-Griebenow E, Zawatzky R, Kahlert H, Brade L, Flad HD, Ernst M. Identification of a novel dendritic cell-like subset of CD64+ CD16+ blood monocytes. Eur J Immunol. 2001;31:48–56.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood. 2007;110:9–17.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
   PubMed Web of Science ®Google Scholar
• Lazzarotto-Silva C, Binato R, Rocher BD, Costa JA, Pizzatti L, Bouzas LF, . Similar proteomic profiles of human mesenchymal stromal cells from different donors. Cytotherapy. 2009;11:268–77.
   PubMed Web of Science ®Google Scholar
• Dragowska WH, Lopes de Menezes DE, Sartor J, Mayer LD. Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: correlation with Western blot analysis. Cytometry. 2000;40:346–52.
   PubMedGoogle Scholar
• Storie I, Sawle A, Goodfellow K, Whitby L, Granger V, Reilly JT, . Flow rate calibration I: a novel approach for performing absolute cell counts. Cytometry B. 2003;55:1–7.
   Google Scholar
• Wan CP, Park CS, Lau BHS. A rapid and simple microfluorometric phagocytosis assay. J Immunol Methods. 1993; 162:1–7.
   PubMed Web of Science ®Google Scholar
• Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, . Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–98.
   PubMed Web of Science ®Google Scholar
• Jones S, Horwood N, Cope A, Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol. 2007;179: 2824–31.
   Google Scholar
• Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745–55.
   PubMed Web of Science ®Google Scholar
• Stec M, Weglarczyk K, Baran J, Zuba E, Mytar B, Pryjma J, . Expansion and differentiation of CD14+ CD16− and CD14++ CD16+ human monocyte subsets from cord blood CD34+ hematopoietic progenitors. J Leukoc Biol. 2007;82: 594–602.
   Google Scholar
• Cutler AJ, Limbani V, Girdlestone J, Navarrete CV. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol. 2010; 185:6617–23.
   PubMed Web of Science ®Google Scholar
• Ding W, Ke C, Wei TD, Zhi-Bo H, He R, Ying C . CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells. Exp Cell Res. 2010;316: 2414–23.
   Google Scholar
• Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002; 23:144–50.
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharm Rev. 2004;56:387–437.
   PubMed Web of Science ®Google Scholar
• Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, . 15-Deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-kB signaling pathway. Proc Natl Acad Sci. 2000;97:4844–9.
   PubMed Web of Science ®Google Scholar
• Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol. 2005;114:100–9.
   PubMed Web of Science ®Google Scholar